



Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-J(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

**Item 1.02 Termination of a Material Definitive Agreement.**

On June 30, 2015, the Company and MLV & Co. LLC, as sales agent, mutually terminated the At Market Issuance Sales Agreement (the “MLV Agreement”) between them which was entered into on April 18, 2013. Through the termination date, the Company sold an aggregate of 2,210,468 shares of its common stock for total gross proceeds of \$3,547,145 pursuant to the MLV Agreement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA  
PHARMACEUTICALS,  
INC.**

By: /s/ Peter Clemens  
Peter A. Clemens  
Senior Vice President

Date: June 30, 2015